Table of Contents
Overview
New York, NY – May 29, 2025 – Global Retinal Vein Occlusion Market size is expected to be worth around US$ 6.6 Billion by 2034 from US$ 3.6 Billion in 2024, growing at a CAGR of 6.5% during the forecast period from 2025 to 2034.
The global Retinal Vein Occlusion (RVO) market is witnessing steady growth, supported by increasing incidence of retinal vascular disorders and advancements in therapeutic interventions. RVO is a common retinal condition characterized by blockage of the veins carrying blood away from the retina, leading to vision impairment. It primarily includes two types: Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO).
The rising prevalence of diabetes, hypertension, and cardiovascular diseases key risk factors for RVO is contributing to increased diagnosis rates globally. Additionally, aging populations and growing awareness about ophthalmic diseases are further expanding the patient pool. Early detection through advanced diagnostic imaging techniques, such as optical coherence tomography (OCT) and fluorescein angiography, is enabling timely clinical intervention.
The market is also being driven by the availability of effective treatments, including intravitreal injections of anti-VEGF agents and corticosteroids, which help in managing macular edema and preventing further vision loss. Ongoing clinical research into sustained-release drug delivery systems and gene therapy is expected to provide new growth avenues over the forecast period. With healthcare infrastructure improving globally and focus increasing on vision preservation, the demand for effective RVO management is anticipated to rise. This positions the Retinal Vein Occlusion market for continued expansion in the coming years.
Key Takeaways
- In 2024, the global Retinal Vein Occlusion (RVO) market generated a revenue of USD 3.56 billion and is projected to reach USD 6.26 billion by 2034, expanding at a CAGR of 6.5% during the forecast period.
- By Disease Type, Central Retinal Vein Occlusion (CRVO) emerged as the leading segment, accounting for 55.2% of the total market share, owing to its higher prevalence and clinical severity.
- Based on Condition, the Non-Ischemic segment held the dominant position, contributing 61.4% of the market share due to its higher diagnosis rates and relatively better prognosis compared to ischemic cases.
- In terms of Diagnosis, Optical Coherence Tomography (OCT) was the most widely used modality, securing a 38.7% share, supported by its high-resolution imaging capabilities for retinal layer evaluation.
- For Treatment, the Anti-Vascular Endothelial Growth Factor (Anti-VEGF) segment led the market with a 44.8% share, driven by its proven efficacy in reducing macular edema and preserving vision.
- Among End-Users, Hospitals and Clinics represented the largest revenue-generating segment with a 52.9% market share, reflecting their central role in delivering specialized ophthalmic care.
- Regionally, North America remained the leading contributor, capturing 41.10% of the global market, supported by robust healthcare systems and high patient awareness levels.
Segmentation Analysis
- Disease Type Analysis: Central Retinal Vein Occlusion (CRVO) led the RVO market due to its severe impact on vision and higher treatment needs. It accounted for a major share, driven by aging populations and rising diabetes prevalence. CRVO’s severity requires advanced therapies like anti-VEGF and corticosteroid implants, supporting market growth. Although BRVO is more prevalent, representing 44.8% of the market, it presents milder symptoms and responds well to treatments like anti-VEGF drugs and laser photocoagulation, maintaining its strong market presence.
- Condition Analysis: Non-Ischemic Retinal Vein Occlusion dominated the market with a 61.4% share in 2024. Its high prevalence and less aggressive progression compared to ischemic types make it more manageable. Patients with non-ischemic RVO often retain vision longer, encouraging timely diagnosis and treatment. This segment benefits from the availability of effective therapies such as anti-VEGF and corticosteroids. Rising awareness, earlier clinical intervention, and favorable outcomes further reinforce the dominance of the non-ischemic condition in the RVO market.
- Diagnosis Analysis: Optical Coherence Tomography (OCT) led the diagnostic segment with a 38.7% market share. Its non-invasive approach, precision, and ability to assess retinal thickness and edema make it essential for RVO diagnosis and monitoring. The preference for OCT is supported by rapid imaging, patient comfort, and advancements in imaging technologies. Compared to fundoscopic exams and fluorescein angiography, OCT provides higher diagnostic value, driving its widespread adoption in clinical settings for accurate and timely evaluation of RVO.
- Treatment Analysis: The Anti-VEGF therapy segment accounted for the largest market share at 44.8% in 2024, reflecting its effectiveness in managing macular edema and preserving vision in RVO patients. These therapies offer long-term benefits and are widely adopted in clinical practice. Ongoing approvals, such as Beovu by Novartis, further support market expansion. Meanwhile, corticosteroid drugs are gaining traction due to their anti-inflammatory properties and long-acting effects, enhancing treatment outcomes and contributing to strong growth in this segment.
- End-User Analysis: Hospitals and Clinics led the end-user segment with a 52.9% market share, driven by access to specialized care and advanced diagnostic tools. Hospitals provide comprehensive treatment options, skilled personnel, and insurance support, making them the primary choice for RVO management. Clinics, especially in developing regions, are also seeing increased patient flow due to better access and ophthalmic services. The growing incidence of RVO continues to strengthen the role of hospitals and clinics in the global market.
Market Segments
By Disease Type
- Central Retinal Vein Occlusion (CRVO)
- Branch Retinal Vein Occlusion (BRVO)
By Condition
- Non-Ischemic
- Ischemic
By Diagnosis
- Optical Coherence Tomography
- Fundoscopic Examination
- Fluorescein Angiography
By Treatment
- Anti-vascular Endothelial Growth Factor (Anti-VEGF)
- Corticosteroid Drugs
- Laser Photocoagulation
- Vitrectomy
- Others
By End-User
- Hospital & Clinics
- Ophthalmic Clinics
- Ambulatory Surgical Centers
Regional Analysis
In 2024, North America accounted for the largest share of the global Retinal Vein Occlusion (RVO) market, capturing 41.10% of total revenue. This dominance is supported by the region’s advanced and highly regulated healthcare infrastructure, which ensures widespread access to diagnostic and treatment services. Market growth is further fueled by strategic collaborations among leading industry players aimed at expanding product portfolios and maintaining high-quality treatment standards.
The increasing prevalence of vision-related disorders continues to drive demand for RVO therapies. According to the Centers for Disease Control and Prevention (CDC), around 12 million adults aged 40 and above in the U.S. suffer from visual impairment. Moreover, the region benefits from strong reimbursement systems, with approximately 84% of the population covered through public or private insurance programs—26% through public plans and 70% through private insurers.
This favorable reimbursement landscape, combined with a growing focus on innovative treatment development, reinforces North America’s leadership position in the global RVO market.
Emerging Trends
- Rising Incidence Linked to Metabolic Risk Factors: The rate of new RVO cases increased notably during 2021–2022, particularly among adults aged 40–64. This rise is attributed more to growing rates of hypertension, diabetes, and other metabolic diseases than to COVID-19 itself.
- Recognition of RVO as a Chronic Condition: Long-term follow-up data show that RVO requires ongoing treatment and monitoring for at least five years to maintain visual gains. It is no longer viewed as a one-time event but as a chronic disease needing personalized care plans.
- Improved Risk Stratification for Bilateral Disease: Recent analyses indicate a 6.3–6.4 % chance of developing RVO in the fellow eye, prompting earlier screening of high-risk patients (older age, hypertension, vascular factors) to prevent bilateral vision loss.
- Introduction of Novel Biologics and Biosimilars
Dual-pathway inhibitors and biosimilars have expanded the treatment toolkit:- Faricimab (Vabysmo®) was granted FDA approval for RVO-related macular edema in April 2022 and received a supplemental approval in 2023 for this indication.
- Ranibizumab-eqrn (Cimerli®) became the first interchangeable biosimilar for ranibizumab, offering a cost-effective option for patients with RVO-associated macular edema.
Use Cases
- Anti-VEGF Injection Therapy: Monthly injections of bevacizumab or aflibercept lead to significant visual improvement in macular edema secondary to RVO. In the SCORE2 trial, visual acuity remained significantly above baseline five years after treatment initiation, underscoring the durability of anti-VEGF therapy.
- Dual-Pathway Biologic Treatment: Faricimab targets both VEGF-A and Ang-2 to reduce vascular leakage and edema. Its approval provides clinicians with an option that may extend treatment intervals and address refractory cases of RVO-associated macular edema.
- Use of Interchangeable Biosimilars: The approval of Cimerli (ranibizumab-eqrn) allows pharmacies to substitute it for reference ranibizumab without additional prescriber authorization, increasing patient access and potentially reducing treatment costs for RVO-related edema.
- Long-Term Personalized Treatment Scheduling: Real-world data show that most RVO patients require periodic injections beyond the first year. Individualized injection schedules, guided by optical coherence tomography (OCT) assessments, help maintain optimal retinal thickness and vision over time.
Conclusion
The global Retinal Vein Occlusion (RVO) market is poised for sustained growth, driven by rising prevalence of metabolic disorders, advancements in diagnostics, and the availability of effective therapies such as anti-VEGF agents.
Increasing recognition of RVO as a chronic condition requiring long-term management, along with the emergence of novel biologics and biosimilars, is reshaping treatment strategies. Strong healthcare infrastructure, particularly in North America, and favorable reimbursement policies further support market expansion. With ongoing innovation and personalized care approaches, the RVO market is expected to continue evolving, ensuring improved patient outcomes and broader access to advanced ophthalmic interventions globally.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
